Analysis of the EGFR mutation status in head and neck squamous cell carcinoma before treatment with gefitinib

Onkologie

Volumn 36, Issue 4, 2013, Pages 161-166

  Bontognali, Sven ^a,b   Pless, Miklos ^a,b,e   Brutsche, Martin H ^a,d,e   Fischer, Claude ^a,c,f   Rochlitz, Christoph ^a,b   Buess, Martin ^a,b,g  

^a Kopf Hals Tumor Zentrum   (Switzerland)

^b Abteilung medizinische Onkologie   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d CANTONAL HOSPITAL WINTERTHUR   (Switzerland)

^e CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^f KANTONSSPITAL GRAUBÜNDEN   (Switzerland)

^g St Claraspital AG   (Switzerland)

Author keywords

EGFR; Gefitinib; Predicitive; Squamous cell carcinoma of the head and neck

Indexed keywords

ADENOSINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GUANINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; UNSPECIFIED SIDE EFFECT;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; POLYMORPHISM, SINGLE NUCLEOTIDE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84876171268     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000349941     Document Type: Article

References (38)

1. Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP: Trends in incidence and prognosis for head and neck cancer in the United States: A site specific analysis of the SEER database. Int J Cancer 2005;114:806-816.
2. Constenla DO, Hill ME, A'Hern RP, Henk JM, Rhys-Evans P, Breach N, Archer D, Gore ME: Chemotherapy for symptom control in recurrent squamous cell carcinoma of the head and neck. Ann Oncol 1997;8:445-449.
3. Argiris A, Li Y, Forastiere A: Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer 2004;101:2222-2229.
4. Arnold DJ, Goodwin WJ, Weed DT, Civantos FJ: Treatment of recurrent and advanced stage squamous cell carcinoma of the head and neck. Semin Radiat Oncol 2004;14:190-195.
5. Hong WK, Schaefer S, Issell B, Cummings C, Luedke D, Bromer R, Fofonoff S, D'Aoust J, Shapshay S, Welch J, Levin E, Vincent M, Vaughan C, Strong S: A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck. Cancer 1983;52:206-210.
6. Forastiere AA, Shank D, Neuberg D, Taylor SG 4th, DeConti RC, Adams G: Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer 1998;82:2270-2274.
7. Guardiola E, Peyrade F, Chaigneau L, Cupissol D, Tchiknavorian X, Bompas E, Madroszyk A, Ronchin P, Schneider M, Bleuze JP, Blay JY, Pivot X: Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer 2004;40:2071-2076.
8. Clavel M, Vermorken JB, Cognetti F, Cappelaere P, de Mulder PH, Schornagel JH, Tueni EA, Verweij J, Wildiers J, Clerico M, et al.: Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1994;5: 521-526.
9. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-1127.
10. León X, Hitt R, Constenla M, Rocca A, Stupp R, Kovács AF, Amellal N, Bessa EH, Bourhis J: A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin Oncol (R Coll Radiol) 2005;17:418-424.
11. Santini J, Formento JL, Francoual M, Milano G, Schneider M, Dassonville O, Demard F: Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 1991;13:132-139.
12. Kalyankrishna S, Grandis JR: Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006;24:2666-2672.
13. Kim ES, Khuri FR, Herbst RS: Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 2001;13:506-513.
14. Cowley GP, Smith JA, Gusterson BA: Increased EGF receptors on human squamous carcinoma cell lines. Br J Cancer 1986;53:223-229.
15. Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD: Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006;12:5064-5073.
16. Mendelsohn J, Baselga J: The EGF receptor family as targets for cancer therapy. Oncogene 2000;19:6550-6565.
17. Baselga J, Averbuch S: ZD1839 ('Iressa') as an anticancer agent. Drugs 2000;60(suppl 1):33-40; discussion 41-42.
18. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, Tortora G: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000;6:2053-2063.
19. Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE: Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21:1980-1987.
20. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL: Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22:77-85.
21. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH: Gefitinib in combination with gemcitabine and cisplatin in advanced non-smallcell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004;22:777-784.
22. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
23. Park JO, Lee SI, Song SY, Kim K, Kim WS, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Lee KS, Park K: Measuring response in solid tumors: comparison of RECIST and WHO response criteria. Jpn J Clin Oncol 2003;33:533-537.
24. Tapia C, Savic S, Bihl M, Rufle A, Zlobec I, Terracciano L, Bubendorf L: [EGFR mutation analysis in non-small-cell lung cancer: Experience from routine diagnostics]. Pathologe 2009;30:384-392.
25. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
26. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11:121-128.
27. Loeffler-Ragg J, Witsch-Baumgartner M, Tzankov A, Hilbe W, Schwentner I, Sprinzl GM, Utermann G, Zwierzina H: Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. Eur J Cancer 2006;42:109-111.
28. Ali MAL, Gunduz M, Nagatsuka H, Gunduz E, Cengiz B, Fukushima K, Beder LB, Demircan K, Fujii M, Yamanaka N: Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma. Cancer Sci 2008;99:1589-1594.
29. Lemos-González Y, Páez de la Cadena M, Rodríguez- Berrocal F, Rodríguez-Piñeiro A, Pallas E, Valverde D: Absence of activating mutations in the EGFR kinase domain in Spanish head and neck cancer patients. Tumor Biol 2007;28:273-279.
30. Kirby AM, A'Hern RP, D'Ambrosio C, Tanay M, Syrigos KN, Rogers SJ, Box C, Eccles SA, Nutting CM, Harrington KJ: Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer. Br J Cancer 2006;94:631-636.
31. Cohen EE, Kane MA, List MA, Brockstein BE, Mehrotra B, Huo D, Mauer AM, Pierce C, Dekker A, Vokes EE: Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2005;11:8418-8424.
32. Murray S, Linardou H, Razis E, Pectasidis D, Fountzilas G: Screening for EGFR mutations in patients with head and neck cancer treated with gefitinib on a compassionate-use program: a Hellenic Cooperative Oncology Group study. Ann Oncol 2006;17(suppl 9):578.
33. Temam S, Kawaguchi H, El-Naggar AK, Jelinek J, Tang H, Liu DD, Lang W, Issa JP, Lee JJ, Mao L: Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 2007;25:2164-2170.
34. Erjala K, Sundvall M, Junttila TT, Zhang N, Savisalo M, Mali P, Kulmala J, Pulkkinen J, Grenman R, Elenius K: Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res 2006;12:4103-4111.
35. Frederick BA, Helfrich BA, Coldren CD, Zheng D, Chan D, Bunn PA, Raben D: Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther 2007;6:1683-1691.
36. Pernas FG, Allen CT, Winters ME, Yan B, Friedman J, Dabir B, Saigal K, Mundinger GS, Xu X, Morris JC: Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer. Clin Cancer Res 2009;15:2361-2372.
37. Wheeler RH JD, Sharma P, et al.: Clinical and molecular phase II study of gefitinib in patients (pts) with recurrent squamous cell cancer of the head and neck (H and N Ca). ASCO Annual Meeting 2005.
38. Wheeler S, Suzuki S, Thomas SM, Sen M, Leeman-Neill RJ, Chiosea S, Kuan C, Bigner D, Gooding W, Lai S: Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation. Oncogene 2010;29:5135-5145.